ew composition of pharmaceutical nutraceutical for antigen-specific prevention and adjunctive therapy of musculoskeletal diseases

New composition of pharmaceutical nutraceutical for antigen-specific prevention and adjunctive therapy of musculoskeletal diseases

I.V. Sarvilina¹, A.M. Lila^2,3, O.A. Gromova^4,5 

¹Medical Center «Novomedicina» LLC, Rostov-on-Don

²V.A. Nasonova Research Institute of Rheumatology, Moscow

³Russian Medical Academy of Continuous Professional Education, Moscow

⁴Federal Research Center «Informatics and Management» of the Russian Academy of Science, Moscow

⁵Lomonosov Moscow State University, Moscow 

The article discusses the current possibilities of using a new composition of pharmaceutical nutraceutical agent, including chondroitin sulfate, glucosamine sulfate and undenatured type II collagen, given the new molecular data on the disease pathogenesis, as well as data on the mechanism of action, pharmacokinetics, efficacy and safety of each of the pharmaceutical nutraceutical components. Special attention is paid to the mechanisms for induction of oral tolerance underlying the development of targeted antigen-specific prevention and adjunctive therapy of osteoarthritis (OA), as well as the interaction of the pharmaceutical nutraceutical components with the immune system in OA. The article shows prospects for the development and administration of new pharmaceutical nutraceuticals due to the widespread prevalance of diseases associated with cartilage degeneration and musculoskeletal system disorder, on the one hand, and the insufficient efficacy of known symptomatic drugs of sustained release, on the other hand. The article also discusses the modern possibilities of patient management with OA based on clinical research data and individual pharmaceutical nutraceutical support.

Keywords: osteoarthritis, chondroitin sulfate, glucosamine sulfate, undenatured type II collagen, pharmaceutical nutraceuticals, oral tolerance.

For citation: Sarvilina I.V., Lila A.M., Gromova O.A. New composition of pharmaceutical nutraceutical for antigen-specific prevention and adjunctive therapy of musculoskeletal diseases. RMJ. 2023;2:44–50.